Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · page 14 of 30
The slide contrasts a chemotherapy-based approach (SMDC) with a radioligand therapy (RLT) approach, highlighting the superior PSA response in the RLT cohort.
Pitch deck · comparison_table · compare_peers · overcrowded density
Slide locked Sign in to view
Slide schematic 9/9
chart 2/2 image 3/3 source-note 2/2 title 2/2
Components 9
bar-vertical bar-vertical illustration illustration photo source-note source-note action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1